Completed PHASE2 INTERVENTIONAL 4-arm NCT01613313

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

Sponsor: Advance Biofactures Corporation

Conditions Lipoma

Interventions Collagenase Clostridium Histolyticum

Updated 8 times since 2017 Last updated: Aug 25, 2016 Started: May 31, 2012 Primary completion: Sep 30, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lipoma and is currently completed. Advance Biofactures Corporation leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Advance Biofactures Corporation
Zachary Gerut

Data source: Gerut, Zachary, M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hewlett, United States